---

Mucormycosis (Black fungus): An alarming sign for COVID-19 patients

Full Text PDF

---

Review Article

Author Details : Ritesh Kumar Srivastav*, Vishal Kumar Vishwakarma, Shiv Kumar Srivastav, Mahesh Prasad, Tarique Mahmood, Chandra Shekhar Singh, Antesh Jha

Volume : 6, Issue : 3, Year : 2021

Article Page : 136-139

https://doi.org/10.18231/j.ijcaap.2021.024

Suggest article by email

Get Permission

Abstract

Mucormycosis (also known as zygomycosis) is a dangerous but uncommon fungal infection caused by a fungus known as mucormycetes. Mucormycosis can be caused by a variety of fungi. Mucormycetes are fungi that belong to the Mucorales scientific order. Molds can be found all over the place. Mucormycosis is a fungal infection that primarily affects persons who have health issues or who use medications that reduce the body's capacity to resist infections and illness. After inhaling fungal spores from the air, it most usually affects the sinuses or lungs. The majority of people are unaffected by these fungus. Breathing in mucormycete spores, on the other hand, can induce an infection in the lungs or sinuses, which can spread to other regions of the body in patients with compromised immune systems. It can also happen as a result of a cut, a burn, or another sort of skin injury. The fatality rate varied based on the patient's underlying condition, the type of fungus, and the affected body part (for example, the mortality rate was 46 percent among people with sinus infections, 76 percent for pulmonary infections, and 96 percent for disseminated mucormycosis). Antifungal medicines such as amphotericin-B, isavuconazole, posaconazole, and various combinations are used to inhibit the growth. Mucormycosis was studied for its spread, symptoms, treatment, prevention, and consequences.
 

Keywords: Mucormycosis, Black fungus, Posaconazole, Isavuconazole

How to cite : Srivastav R K, Vishwakarma V K, Srivastav S K, Prasad M, Mahmood T, Singh C S, Jha A, Mucormycosis (Black fungus): An alarming sign for COVID-19 patients. IP Int J Compr Adv Pharmacol 2021;6(3):136-139

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.